

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Dipeptiven, concentrate for solution for infusion

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 ml contains:

Active substance	Quantity
-------------------------	-----------------

N(2)-L-alanyl-L-glutamine	200 mg (= 82.0 mg L-alanine, 134.6 mg
---------------------------	---------------------------------------

L-glutamine) theoretical osmolarity : 921 mosmol/l

titration acidity : 90 - 105 mmol NaOH/l

pH value : 5.4 - 6.0

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Concentrate for solution for

infusion. A clear colourless

solution.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Dipeptiven is indicated as part of a clinical nutrition regimen in patients in hypercatabolic and/or hypermetabolic states. It should be given together with parenteral or enteral nutrition or a combination of both.

4.2 Posology and method of administration

Solution for infusion after mixture with a compatible infusion solution.

Solutions of mixtures with an osmolarity above 800 mosmol/l should be infused by the central venous route.

Adults

Dipeptiven is administered parallel with parenteral nutrition or enteral nutrition or a combination of both. Dosage depends on the severity of the catabolic state and on amino acids/protein requirement.

A maximum daily dosage of 2 g amino acids and/or protein per kg body weight should not be exceeded in parenteral/enteral nutrition. The supply of alanine and glutamine via Dipeptiven should be taken into consideration in the calculation. The proportion of the amino acids supplied through Dipeptiven should not exceed approx. 30% of the total amino acids/protein supply.

Daily dose

1.5 - 2.5 ml of Dipeptiven per kg body weight (equivalent to 0.3 - 0.5 g N(2)-L-alanyl-L-glutamine per kg body weight). This equates to 100 to 175 ml Dipeptiven for a patient of 70 kg body weight.

Maximum daily dose: 2.5 ml equivalent to 0.5 g N(2)-L-alanyl-L-glutamine of Dipeptiven per kg body weight.

The maximum daily dose of 0.5 g N(2)-L-alanyl-L-glutamine per kg body weight should be administered in combination with at least 1.0 g amino acids/protein, per kg body weight per day. With the amino acids from Dipeptiven included, this results in a daily dosage of at least 1.5 g amino acids/protein per kg body weight.

The following adjustments are examples for the supply with Dipeptiven and amino acids through the parenteral nutrition solution, and/or protein through enteral nutrition formula:

Amino acids/protein requirement 1.2 g/kg body weight per day:
0.8 g amino acids/protein + 0.4 g N(2)-L-alanyl-L-glutamine per kg body weight.

Amino acids/protein requirement 1.5 g/kg body weight per day:
1.0 g amino acids/protein + 0.5 g N(2)-L-alanyl-L-glutamine per kg body weight.

Amino acids/protein requirement 2 g/kg body weight per day:
1.5 g amino acids/protein + 0.5 g N(2)-L-alanyl-L-glutamine per kg body weight.

Dipeptiven is an infusion solution concentrate which is not designed for

direct administration. Patients with total parenteral nutrition

The rate of infusion depends on that of the carrier solution and should not exceed 0.1 g amino acids/kg body weight per hour.

Dipeptiven should be mixed with a compatible amino acid carrier solution or an amino acid containing infusion regimen prior to administration.

Patients with total enteral nutrition

Dipeptiven is continuously infused over 20-24 hours per day. For peripheral venous infusion, dilute Dipeptiven to an osmolarity ≤ 800 mosmol/l (e.g. 100 ml Dipeptiven + 100 ml saline).

Patients with combined enteral and parenteral nutrition

The full daily dosage of Dipeptiven should be administered with the parenteral nutrition, i.e. mixed with a compatible amino acid solution or an amino acid containing infusion regimen prior to administration.

The rate of infusion depends on that of the carrier solution and should be adjusted according to the proportions of parenteral and enteral nutrition.

Duration of administration

The duration of use should not exceed 3 weeks.

Paediatric population

Safety and efficacy in children have not been established.

4.3 Contraindications

Dipeptiven should not be administered to patients with severe renal insufficiency

(creatinine clearance < 25 ml/minute), severe hepatic insufficiency, circulatory shock, hypoxia, multiple organ failure, severe metabolic acidosis or known hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

1

4.4 Special warnings and precautions for use

For a safe administration the maximum dose of Dipeptiven should not exceed 2.5 ml (corresponding to 0.5 g N(2)-L-alanyl-L-glutamine) per kg body weight per day (see section 4.2, 4.9 and 5.1).

Dipeptiven should only be used as part of clinical nutrition, and its dosage is limited by the amount of protein/amino acids provided by nutrition (see section 4.2). Whenever the clinical condition does not allow nutrition (e.g., circulatory shock, hypoxia, unstable critically ill patients, severe metabolic acidosis) Dipeptiven should not be administered. Oral/enteral intake of glutamine-supplemented formulas in combination with parenteral nutrition should be taken into consideration for calculation of the prescribed dose of Dipeptiven.

2

It is advisable to regularly monitor liver function parameters in patients with compensated hepatic insufficiency.

As there is currently insufficient data on administration of Dipeptiven to pregnant women, nursing mothers and children, administration of the preparation in these patient groups is not recommended.

Serum electrolytes, serum osmolarity, water balance, acid-base status, creatinine clearance, urea, as well as liver function tests (alkaline phosphatase, ALT, AST) and possible symptoms of hyperammonaemia should be controlled.

3

The choice of a peripheral or central vein depends on the final osmolarity of the mixture. The generally accepted limit for peripheral infusion is about 800 mosmol/l but it varies considerably with the age and general condition of the patient and the characteristics of the peripheral veins.

Experience with the use of Dipeptiven for longer periods than nine days is limited.

4.5 Interaction with other medicinal products and other forms of interaction

No interactions are known to date.

4.6 Fertility, pregnancy and lactation

Due to lack of experience, Dipeptiven should not be administered during pregnancy and lactation.

4.7 Effects on ability to drive and use machines

Not applicable

4.8 Undesirable effects

None known when correctly administered.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system

[To be completed nationally]

4.9 Overdose

As with other infusion solutions, chills, nausea and vomiting can occur, when the infusion rate of Dipeptiven is exceeded.

Infusion shall be stopped immediately in this case.

Experience from a study in critically ill patients with at least two organ failures at admission, receiving the maximum approved daily intravenous infusion of Dipeptiven (0.5 g alanyl-glutamine/kg/day) together with a high dose of enteral glutamine (30 g) provided as a mixture of alanyl-glutamine and glycyl-glutamine and without appropriate clinical nutrition, has shown an increase in serious side effects. 4

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Amino acids – concentrate for solution for parenteral nutrition, ATC code: B05X B02

The dipeptide N(2)-L-alanyl-L-glutamine is endogenously split into the amino acids glutamine and alanine hereby supplying glutamine with infusion solutions for parenteral nutrition. The released amino acids flow as nutrients into their respective body pools and are metabolised according to the needs of the organism. Many disease conditions in which clinical nutrition is indicated are accompanied by a glutamine depletion.

In a large multicenter study, critically ill adult patients with at least two organ failures at admission and requiring mechanical ventilation received either supplemental glutamine alone, antioxidants, glutamine and antioxidants, or placebo. In the glutamine groups, patients concomitantly received parenteral and enteral glutamine in their maximally allowed amounts exceeding the recommended dose by two-fold. Overall, mortality for the entire study population at 28 days, the primary endpoint, was not statistically significantly different between the groups. However, 6-month mortality, in a retrospective analysis, was tendentially increased in patients receiving the combined very high total dose of glutamine during unresuscitated shock and renal failure; glutamine and nutrition should not be used in unresuscitated shock accompanied by renal failure (see section 4.9). Under these specific circumstances the patient's ability to metabolize glutamine seems to have been exceeded (see also section 4.4). 5

5.2 Pharmacokinetic properties

N(2)-L-alanyl-L-glutamine is rapidly split into alanine and glutamine after infusion. In man, half-lives of between 2.4 and 3.8 min (in terminal renal insufficiency 4.2 min) and a plasma clearance of between 1.6 and 2.7 l/min were determined. The disappearance of the dipeptide was accompanied by an equimolar increase of the corresponding free amino acids. Hydrolysis probably takes place exclusively in the extracellular space. Renal elimination of N(2)-L-alanyl-L-glutamine under constant infusion is below 5% and thus the same as that of infused amino acids.

5.3 Preclinical safety data

Acute and subchronic toxicity: A matrix of dosage finding tests were conducted on rats and dogs over 1 to 7 days. In the rats, infusion of 50 ml/kg b.w. of a 10%, 15%, 20% and 30% solution of N(2)-L-alanyl-L-glutamine over 4h/day led to tonic spasms, increased respiratory rate and exitus. Infusion of 50 ml/kg b.w. of a 10% solution (5 g N(2)-L-alanyl-L-glutamine/kg b.w.) resulted in necrotic areas at the infusion site, reduced body weight and yellowing of the kidneys in the rats (6 h/day), and a temporary increase in heart rate in the dog (8 h/day).

Investigations were carried out in dogs (8h/day) and in rats (6h/day) with 0.5 and 1.5 g N(2)-L-alanyl-L-glutamine/kg b.w. per day i.v. over 13 weeks and with 4.5 g N(2)-L-alanyl-L-glutamine/kg b.w. per day i.v. over 6 weeks. In the dogs, vomiting occurred. With the high dose tonic or tonic-clonic cramps, increased salivation, ataxia, sedation, and lateral position were observed.

Mutagenic and tumorigenic potential: In vitro and in vivo test gave no indications of mutagenic potential.

Studies investigating the tumorigenic potential were not carried out. Carcinogenic effects are not to be expected.

Reproduction toxicity: In animal trials, no indications of teratogenic or other embryotoxic and peripostnatal injuries could be observed up to a dosage of 1.6 g N(2)-L-alanyl-L-glutamine/kg b.w. per day.

Local tolerance: Following repeated i.v. infusion of N(2)-L-alanine-L-glutamine (5 and 10% solution) over 13 weeks, intolerance reactions occurred at the infusion sites (swellings, discolourations, necroses) in the rats and dogs from 0.5 g/kg b.w. onwards. Histopathologically, substance-induced inflammatory reactions with mild to fully developed dermatitis purulenta necroticans and osteomalacia of the tail vertebrae, thrombophlebitis and periphlebitis, were observed in the rats. In the dog, perivascular inflammatory reactions and, occasionally, vessel blockage were observed.

The tests conducted on the dog on local tolerance after a single, intraarterial, paravenous and intramuscular administration gave no indications of unusual intolerance reactions with incorrect administration.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Water for injection.

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf-life

2 years.

To be used immediately after the bottle is opened.

6

Dipeptiven is not to be stored after addition of other components.

6.4 Special precautions for storage

Do not store above

25°C. Store in the

original package.

6.5 Nature and content of container

Glass bottles

1 x 50 ml, 10 x 50 ml

1 x 100 ml, 10 x100

ml Type II, colourless

glass Rubber

closure.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Dipeptiven is an infusion solution concentrate which is not designed for direct administration.

The container and the solution should be inspected visually prior to use. Use only clear, particle-free solution and undamaged container. For single use only.

The addition of the concentrate to the carrier solution prior to application should take place under aseptic conditions.

Thorough mixing and compatibility must be ensured. Unused solution

should be disposed of. Dipeptiven is infused with the carrier solution. For

details see section 4.2.

7. MARKETING AUTHORISATION HOLDER

[To be completed nationally]

8. MARKETING AUTHORISATION NUMBERS

[To be completed nationally]

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

Date of first authorisation: 1995-03-29

Date of latest renewal: [To be completed nationally]

10. DATE OF REVISION OF THE TEXT

22-01-2026